Moderna Balance Sheet
MRNA / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 10 fiscal years. All figures from audited SEC 10-K filings.
Moderna had $12.3B in total assets and $8.7B in shareholders' equity as of FY2025. Total debt was $590M against $2.6B in cash, resulting in a $2.0B net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.6B | $1.9B | $2.9B | $6.8B | $2.6B | $2.6B | $236.0M | $658.4M | $134.9M | $50.1M |
| Accounts Receivable | $184.0M | $358.0M | $892.0M | $1.4B | $3.2B | $1.4B | $5.4M | $11.7M | $11.9M | - |
| Inventory | $153.0M | $117.0M | $202.0M | $949.0M | $1.4B | $47.0M | $0 | - | - | - |
| Current Assets | $6.5B | $8.1B | $10.3B | $13.4B | $16.1B | $6.3B | $1.1B | $1.6B | $783.2M | - |
| PP&E (Net) | - | - | - | $2.0B | $1.2B | - | $209.5M | $212.0M | $139.0M | - |
| Goodwill | $52.0M | $52.0M | $52.0M | - | - | - | - | - | - | - |
| Total Assets | $12.3B | $14.1B | $18.4B | $25.9B | $24.7B | $7.3B | $1.6B | $2.0B | $1.1B | - |
| Current Liabilities | $2.0B | $2.2B | $3.0B | $4.9B | $9.1B | $4.4B | $143.1M | $222.8M | $191.5M | - |
| Total Debt | $590.0M | $0 | - | - | - | - | - | - | - | - |
| Shareholders' Equity | $8.7B | $10.9B | $13.9B | $2.6B | $1.2B | $2.6B | $1.2B | $1.5B | -$551.4M | -$334.8M |